Arkolith/Insider Trading/BTTX/Form 4

Wynholds Kristin

Chief Product OfficerBetter Therapeutics, Inc. (BTTX) · full profile →Form 4 · filed Dec 2, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 30, 2022Grant(A)4K$1.24$5K99K
May 31, 2022Grant(A)5K$1.54$8K95K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-037418) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML